Draflazine

This classification denotes a cardiotonic agent and antiplatelet agent with the molecular formula C30H33Cl2F2N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0Y25DT968Y, chemically known as 1-piperazineacetamide, 2-(aminocarbonyl)-n-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)pentyl)-,(+-)- but generally known as draflazine, which bears US NIH Compound Identifier 60849. European Medicines Agency schedules Draflazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06395MIG. The term DRAFLAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). DRAFLAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule draflazine under HS 29335995 and SITC 51576. As of Q4 2014, DRAFLAZINE remains the US FDA Preferred Term for this commodity. Draflazine bears US NLM identifiers UMLS ID C0209869 and NCI Concept Code C76030. SMILES: CLC1C(NC(=O)CN2C(CN(CC2)CCCCC(C2CCC(F)CC2)C2CCC(F)CC2)C(=O)N)C(CL)CC(N)C1.